PET/CT in therapy evaluation of patients with lung cancer

Natasha Hemicke Langer; Tine Nøhr Christensen; Seppo W Langer; Andreas Kjaer; Barbara Malene Fischer

doi:10.1586/14737140.2014.883280

PET/CT in therapy evaluation of patients with lung cancer

Natasha Hemicke Langer, Tine Nøhr Christensen, Seppo W Langer, Andreas Kjaer, Barbara Malene Fischer

5 Citations (Scopus)

Abstract

FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

Original language	English
Journal	Expert Review of Anticancer Therapy
Volume	14
Issue number	5
Pages (from-to)	595-620
Number of pages	26
ISSN	1473-7140
DOIs	https://doi.org/10.1586/14737140.2014.883280
Publication status	Published - May 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2014.883280

Cite this

@article{8a17c044e6c541349b77f35862002ba5,

title = "PET/CT in therapy evaluation of patients with lung cancer",

abstract = "FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.",

keywords = "Humans, Lung Neoplasms, Multimodal Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed",

author = "Langer, {Natasha Hemicke} and Christensen, {Tine N{\o}hr} and Langer, {Seppo W} and Andreas Kjaer and Fischer, {Barbara Malene}",

year = "2014",

month = may,

doi = "10.1586/14737140.2014.883280",

language = "English",

volume = "14",

pages = "595--620",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor & Francis",

number = "5",

}

TY - JOUR

T1 - PET/CT in therapy evaluation of patients with lung cancer

AU - Langer, Natasha Hemicke

AU - Christensen, Tine Nøhr

AU - Langer, Seppo W

AU - Kjaer, Andreas

AU - Fischer, Barbara Malene

PY - 2014/5

Y1 - 2014/5

N2 - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

AB - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

KW - Humans

KW - Lung Neoplasms

KW - Multimodal Imaging

KW - Positron-Emission Tomography

KW - Tomography, X-Ray Computed

U2 - 10.1586/14737140.2014.883280

DO - 10.1586/14737140.2014.883280

M3 - Journal article

C2 - 24702537

SN - 1473-7140

VL - 14

SP - 595

EP - 620

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 5

ER -

PET/CT in therapy evaluation of patients with lung cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this